Jan Öhrström
Chairman at ONWARD MEDICAL N.V.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Grégoire Courtine | M | 49 |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 10 years |
| Vincent Delattre | M | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 10 years |
| Heather Franklin | F | 58 |
Blaze Bioscience, Inc.
 Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA.
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 23 years |
| Lars Fruergaard Jorgensen | M | 58 | 33 years | |
| Tom Maguire | M | - | 8 years | |
| Fredericus Colen | M | 71 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 7 years |
| John Paul de Koning | M | 55 |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 8 years |
| Ian Curtis | M | 56 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 5 years |
| Roel Bulthuis | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | - |
| David Marver | M | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 4 years |
| Andy Dolan | M | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 3 years |
| Mila Lobanova | F | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Karsten Munk Knudsen | M | 53 | 25 years | |
| Henrik Ehlers Wulff | M | 54 | 25 years | |
| James C. Towne | M | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Per Stahl Skov | M | 78 |
University of Copenhagen
| 44 years |
| Vivian Riefberg | F | 63 | 2 years | |
| Regina Hodits | M | 53 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 8 years |
| Dennis M. Miller | M | 61 |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA.
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | - |
| Peter Jan Elvire Byloos | M | 56 | 6 years | |
| John Murphy | M | 57 | 4 years | |
| Guillem Laporta | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Alex Gold | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Kristina Dziekan | F | - | 2 years | |
| Erika Ross | M | - | 1 years | |
| Mary Ellen Hughes | F | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Abbas Ardehali | M | - | 6 years | |
| Sarah Moore | F | - | 1 years | |
| Jan Disbergen | M | - |
Polyganics BV
 Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | 11 years |
| Claudia Jochheim | M | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Jeffrey Lawson | M | 60 |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | 1 years |
| Ferrand Patrice | M | - | 5 years | |
| Patrick van Beneden | M | 62 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | - |
| Annemieke J. Wouterse | F | - |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | 12 years |
| Erin Elizabeth Gainer | M | 50 | 6 years | |
| Casper Breum | M | 57 |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | 4 years |
| Romke S. R. Ribbels | M | - |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | 15 years |
| Ralph Voncken | M | 53 |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | - |
| Camilla Sylvest | F | 52 | 28 years | |
| Khaled Bahi | M | - | 1 years | |
| Maziar Mike Doustdar | M | 54 | 32 years | |
| Julia Novak | M | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Simone Botti | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Oskar Slotboom | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Lars Gredsted | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| William D. Spotnitz | M | - | 9 years | |
| Marie-Claire Fritsch | F | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Williams | M | 66 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 6 years |
| Jakob Riis | M | 58 | 21 years | |
| Etienne Binant | M | - | - | |
| Suzanne M. Shema | F | 66 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 11 years |
| Mads Krogsgaard Thomsen | M | 63 |
University of Copenhagen
| 38 years |
| Thomas Dyrberg | M | 69 |
University of Copenhagen
| 18 years |
| James Johnson | M | 67 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 9 years |
| Martin Jensen | M | 64 |
University of Copenhagen
| 10 years |
| Marie-Claire Janailhac-Fritsch | F | 68 | - | |
| Steen Meier Rønborg | M | 70 |
University of Copenhagen
| 3 years |
| Carsten Hellmann | M | 60 | - | |
| Caroline Lang | F | - | - | |
| Jean-Yves Quentel | M | 54 | - | |
| Pieter H. Reitsma | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Carine Cochereau | F | - | 1 years | |
| Jesper Brandgaard | M | 60 | 20 years | |
| Harry Penner | M | 78 | 8 years | |
| Kåre Bo Stolt | M | 60 |
University of Copenhagen
| 3 years |
| Bente Juel Riis | M | - |
University of Copenhagen
| 4 years |
| Jørgen Nergaard Gøl | M | - |
University of Copenhagen
| 4 years |
| Karsten Witt | M | 68 |
University of Copenhagen
| 3 years |
| Annette Stube | F | 57 | 11 years | |
| Eivind Kolding | M | 64 |
University of Copenhagen
| 3 years |
| Gitte L. Pedersen | F | 61 | 10 years | |
| Janne Thyø Thomsen | F | 67 |
University of Copenhagen
| 3 years |
| Liselotte Hyveled | F | 58 | 26 years | |
| Peder Andersen | M | 72 |
University of Copenhagen
| 3 years |
| Zaiton binti Jamaluddin | F | 65 | 8 years | |
| Peter Jens Lindholm Kurtzhals | M | - | 28 years | |
| Melis Cosan Baban | M | - |
University of Copenhagen
| 3 years |
| Jan Mikkelsen | M | 65 | 11 years | |
| Christian Sagild | M | 64 |
University of Copenhagen
| 1 years |
| Lars Green | M | 57 | 27 years | |
| Bjørn Høi Jensen | M | 62 |
University of Copenhagen
| 1 years |
| Peter David Suzdak | M | 65 | 7 years | |
| Lars Rebien Sørensen | M | 69 |
University of Copenhagen
| 1 years |
| Lone Fønss Schrøder | F | 64 |
University of Copenhagen
| 3 years |
| Niels Crone | M | - |
University of Copenhagen
| 1 years |
| Jeppe Fonager Christiansen | M | 64 |
University of Copenhagen
| 1 years |
| Lars Kolind | M | 77 |
University of Copenhagen
| 7 years |
| Kirsten Drejer | M | 68 | 9 years | |
| Andreas Hasle | M | 69 |
University of Copenhagen
| 4 years |
| Thomas Dywremose | M | - |
University of Copenhagen
| 4 years |
| Susanne Høiberg | M | - |
University of Copenhagen
| 4 years |
| Brian R. Burr | M | - |
University of Copenhagen
| 4 years |
| Stig Strøbæk | M | 60 | 30 years | |
| Karsten Kielland | M | - |
University of Copenhagen
| 4 years |
| Louis Illum Honoré | M | 62 |
University of Copenhagen
| 4 years |
| Lisbeth Hald | F | - |
University of Copenhagen
| 4 years |
| Lillan Rejkjaer | M | - |
University of Copenhagen
| 3 years |
| Birgit Kjældgaard Giwercman | M | - |
University of Copenhagen
| 3 years |
| Haibin Zheng | M | - |
University of Copenhagen
| 3 years |
| Susanne Hayes | F | - | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Denmark | 50 | 50.00% |
| Netherlands | 27 | 27.00% |
| France | 12 | 12.00% |
| United States | 10 | 10.00% |
| Switzerland | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jan Öhrström
- Personal Network
